EKTERLY’s Blockbuster Start: KalVista’s Fourth Quarter Revenue Points to Shifting HAE Treatment Landscape
Q4 Revenue Hits $35 Million as EKTERLY’s U.S. Launch Accelerates
KalVista Pharmaceuticals (NASDAQ: KALV) delivered a strong market update as of 11:15 AM today, revealing preliminary unaudited global net product revenue for EKTERLY (sebetralstat) of $35 million for the fourth quarter and $49 million for the full year 2025. The launch of EKTERLY, the first and only oral on-demand treatment for hereditary angioedema (HAE), is translating into rapid commercial results, with 1,318 U.S. patient start forms and 580 unique prescribers since its July 2025 debut. The surge in refill prescriptions—surpassing new scripts for the first time—underscores sticky demand and positive patient experiences.
| Metric | Fourth Quarter 2025 | Full Year 2025 |
|---|---|---|
| Global EKTERLY Revenue (Unaudited) | $35 million | $49 million |
| U.S. Patient Start Forms (Cumulative) | 1,318 | 1,318 |
| Unique U.S. Prescribers | 580 | 580 |
Refill Trends and International Uptake Signal Confidence in EKTERLY
Beyond U.S. borders, Germany is mirroring the U.S. pattern of quick uptake, lending credibility to management’s optimism about future launches in other major markets through 2026. Notably, prescription refills now drive the majority of sales, decreasing launch-phase reliance on first-time prescribers and hinting at building real-world loyalty among both patients and physicians. KalVista’s CCO Nicole Sweeny pointed to patient satisfaction as the driving force behind these refill trends, marking a significant vote of confidence for the therapy’s future as a foundational HAE treatment option.
Strategic Partnerships Expand EKTERLY’s Global Reach
To further accelerate growth, KalVista has inked a third ex-U.S. commercial partnership within 10 months, this time with Multicare Pharma for Latin America. The goal: regulatory approval and distribution across Brazil, Argentina, Colombia, and Mexico. This follows distribution agreements for Japan and Canada and recent market approvals covering not just the U.S., but also the European Union, U.K., Switzerland, Australia, Singapore, and Japan. The global rollout strategy is clear and aggressive.
Pipeline Progress: Pediatric Expansion Ahead of Schedule
In addition to commercial updates, KalVista reported it has finished enrolling the pivotal KONFIDENT-KID Phase 3 trial for pediatric HAE patients (aged 2-11) a full year ahead of schedule. A regulatory filing in this population is now targeted for Q3 2026, with a U.S. launch likely in 2027, positioning EKTERLY as a standard across both adult and pediatric segments worldwide.
Key Takeaways: Momentum and Market Opportunity
EKTERLY’s early launch data reveals momentum likely to reshape the HAE treatment market. Refills outpacing first prescriptions hint at high user retention, and international adoption is progressing ahead of schedule. With regulatory filings on the horizon and partnerships rapidly expanding global access, KalVista is positioning itself as a leader in on-demand HAE therapy. Investors and healthcare observers should keep an eye on refill rates and the next phases of the global rollout, particularly as EKTERLY prepares to address unmet needs among pediatric patients. For now, the numbers speak for themselves—EKTERLY’s launch is off to a robust and promising start.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI